1.1A Senate resolution
1.2designating May 1 to 7, 2023, as Tardive Dyskinesia Awareness Week.
1.3WHEREAS, many people with serious mental health conditions, such as bipolar disorder,
1.4major depression, schizophrenia, and schizoaffective disorder, or gastrointestinal disorders, including
1.5gastroparesis, nausea, and vomiting, may be treated with medications that work as dopamine receptor
1.6blocking agents (DRBAs), including antipsychotics; and
1.7WHEREAS, while ongoing treatment with these medications can be necessary, prolonged
1.8use can also lead to tardive dyskinesia (TD), an involuntary movement disorder that is characterized
1.9by uncontrollable, abnormal, and repetitive movements of the face, torso, or other body parts; and
1.10WHEREAS, it is estimated that TD affects approximately 600,000 people in the United
1.11States, and approximately 70 percent of people with TD have not been diagnosed, making it important
1.12to raise awareness about the symptoms and impact of TD because even mild symptoms of TD can
1.13have physical, social, and emotional consequences; and
1.14WHEREAS, it is important that people taking DRBAs be monitored for TD, as regular
1.15screening for TD in these patients is recommended by the American Psychiatric Association; and
1.16WHEREAS, clinical research has led to the availability of two treatments for adults with TD
1.17by the United States Food and Drug Administration; and
1.18WHEREAS, the Minnesota State Senate can raise awareness of tardive dyskinesia in the
1.19public and medical community; NOW, THEREFORE,
1.20BE IT RESOLVED by the Senate of the State of Minnesota that it designates May 1 to 7,
1.212023, as Tardive Dyskinesia Awareness Week and encourages each individual in the state of
1.22Minnesota to become better informed about and aware of tardive dyskinesia.